Abstract
Cyclic nucleotide phosphodiesterases (PDEs) are a superfamily of enzymes that are involved in the regulation of the intracellular second messengers cyclic AMP (cAMP) and cyclic GMP (cGMP) by controlling their rates of hydrolysis. There are 11 different PDE families and each family typically has multiple isoforms and splice variants. The PDEs differ in their structures, distribution, modes of regulation, and sensitivity to inhibitors. Since PDEs have been shown to play distinct roles in processes of emotion and related learning and memory processes, selective PDE inhibitors, by preventing the breakdown of cAMP and/or cGMP, modulate mood and related cognitive activity. This review discusses the current state and future development in the burgeoning field of PDEs in the central nervous system. It is becoming increasingly clear that PDE inhibitors have therapeutic potential for the treatment of neuropsychiatric disorders involving disturbances of mood, emotion, and cognition.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abel T, Nguyen PV, Barad M, Deuel TAS, Kandel ER (1997) Genetic demonstration of a role for PKA in the late phase of LTP and in hippocampus based long term memory. Cell 88:615–626
Ahmed T, Frey JU (2005) Phosphodiesterase 4B (PDE4B) and cAMP-level regulation within different tissue fractions of rat hippocampal slices during long-term potentiation in vitro. Brain Res 1041:212–222
Aizawa T, Wei H, Miano JM, Abe J, Berk BC, Yan C (2003) Role of phosphodiesterase 3 in NO/cGMP-mediated antiinflammatory effects in vascular smooth muscle cells. Circ Res 93:406–413
Akhondzadeh S (1999) Hippocampal synaptic plasticity and cognition. J Clin Pharm Ther 24:241–248
Anjum R, Blenis J (2008) The RSK family of kinases: emerging roles in cellular signaling. Nat Rev Mol Cell Biol 9:747–758
Bach ME, Bach ME, Barad M, Son H, Zhuo M, Lu YF, Shih R, Mansuy I, Hawkins RD, Kandel ER (1999) Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long-term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway. Proc Natl Acad Sci USA 96:5280–5285
Baillie GS, MacKenzie SJ, McPhee I, Houslay MD (2000) Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases. Br J Pharmacol 13:811–819
Barad M, Bourtchouladze R, Winder DG, Golan H, Kandel E (1998) Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proc Natl Acad Sci USA 95:15020–15025
Baratti CM, Boccia MM (1999) Effects of sildenafi l on long-term retention of an inhibitory avoidance response in mice. Behav Pharmacol 10:731–737
Barnette MS, Underwood DC (2000) New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease. Curr Opin Pulm Med 6:164–169
Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58:488–520
Birnbaum SG, Gobeske KT, Auerbach J, Taylor JR, Arnsten AFT (1999) A role for norepinephrine in stress-induced cognitive deficits: alpha-1-adrenoceptor mediation in prefrontal cortex. Biol Psychiatry 46:1266–1274
Blokland A, Schreiber R, Prickaerts J (2006) Improving memory: a role for phosphodiesterases. Curr Pharm Des 12:2511–2523
Boess FG, Hendrix M, van der Staay FJ, Erb C, Schreiber R, van Staveren W, de Vente J, Prickaerts J, Blokland A, Koenig G (2004) Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 47:1081–1092
Bolger G, Michaeli T, Martins T, St John T, Steiner B, Rodgers L, Riggs M, Wigler M, Ferguson K (1993) A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs. Mol Cell Biol 13:6558–6571
Bolger GB, Rodgers L, Riggs M (1994) Differential CNS expression of alternative mRNA isoforms of the mammalian genes encoding cAMP-specific phosphodiesterases. Gene 149:237–244
Bon CL, Garthwaite J (2003) On the role of nitric oxide in hippocampal long-term potentiation. J Neurosci 23:1941–1948
Bos JL (2006) Epac proteins: multi-purpose cAMP targets. Trends Biochem Sci 31:680–686
Bourtchouladze R, Lidge R, Catapano R, Stanley J, Gossweiler S, Romashko D, Scott R (2003) A mouse model of Rubinstein–Taybi syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4. Proc Natl Acad Sci USA 100:10518–10522
Bouton ME, Westbrook RF, Corcoran KA, Maren S (2006) Contextual and temporal modulation of extinction: behavioral and biological mechanisms. Biol Psychiatry 60:352–360
Brink CB, Clapton JD, Eagar BE, Harvey BH (2008) Appearance of antidepressant-like effect by sildenafil in rats after central muscarinic receptor blockade: evidence from behavioural and neuro-receptor studies. J Neural Transm 115:117–125
Bruel-Jungerman E, Davis S, Rampon C, Laroche S (2006) Long-term potentiation enhances neurogenesis in the adult dentate gyrus. J Neurosci 26:5888–5893
Bruel-Jungerman E, Rampon C, Laroche S (2007) Adult hippocampal neurogenesis, synaptic plasticity and memory: facts and hypotheses. Rev Neurosci 18:93–114
Bunge SA, Ochsner KN, Desmond JE, Glover GH, Gabrieli JD (2001) Prefrontal regions involved in keeping information in and out of mind. Brain 124:2074–2086
Cassel JC, Cassel S, Galani R, Kelche C, Will B, Jarrard L (1998) Fimbria-fornix vs. selective hippocampal lesions in rats: effects on locomotor activity and spatial learning and memory. Neurobiol Learn Mem 69:22–45
Chen A, Muzzio IA, Malleret G, Bartsch D, Verbitsky M, Pavlidis P, Yonan AL, Vronskaya S, Grody MB, Cepeda I, Gilliam TC, Kandel ER (2003) Inducible enhancement of memory storage and synaptic plasticity in transgenic mice expressing an inhibitor of ATF4 (CREB-2) and C/EBP proteins. Neuron 39:655–669
Chen CC, Yang CH, Huang CC, Hsu KS (2010) Acute stress impairs hippocampal mossy fiber-CA3 long-term potentiation by enhancing cAMP-specific phosphodiesterase 4 activity. Neuropsychopharmacology 35:1605–1617
Cheng YF, Wang C, Lin HB, Li YF, Huang Y, Xu JP, Zhang HT (2010) Inhibition of phosphodiesterase-4 reverses memory deficits produced by Abeta 25-35 or Abeta1-40 peptide in rats. Psychopharmacology 212:181–191
Cherry JA, Davis RL (1999) Cyclic AMP phosphodiesterases are location in region of the mouse brain associate with reinforcement, movement, and effect. J Comp Neurol 407:287–301
Clapcote SJ, Lipina TV, Millar JK, Mackie S, Christie S, Ogawa F, Lerch JP, Trimble K, Uchiyama M, Sakuraba Y, Kaneda H, Shiroishi T, Houslay MD, Henkelman RM, Sled JG, Gondo Y, Porteous DJ, Roder JC (2007) Behavioral phenotypes of Disc1 missense mutations in mice. Neuron 54:387–402
Conti M, Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76:481–511
Conti M, Nemoz G, Sette C, Vicini E (1995) Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocr Rev 16:370–389
Conti M, Richter W, Mehats C, Livera G, Park JY, Jin C (2003) Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 278:5493–5496
Coquil JF, Franks DJ, Wells JN, Dupuis M, Hamet P (1980) Characteristics of a new binding protein distinct from the kinase for guanosine 3, 5-monophosphate in rat platelets. Biochim Biophys Acta 631:148–165
Coven E, Ni Y, Widnell KL, Chen J, Walker WH, Habener JF, Nestler EJ (1998) Cell type-specific regulation of CREB gene expression: mutational analysis of CREB promoter activity. J Neurochem 71:1865–1874
Crowe SM, Streetman DS (2002) Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 162:1349–1360
De Vente J, Hopkins DA, Markerink-van Ittersum M, Steinbusch HWM (1996) Effects of the 3′, 5′-phosphodiesterase inhibitors isobutylmethylxanthine and zaprinast on NO-mediated cGMP accumulation in the hippocampus slice preparation: an immunocytochemical study. J Chem Neuroanat 10:241–248
DeNoble VJ (1987) Vinpocitine enhances retrieval of a step-through passive avoidance response in rats. Pharmacol Biochem Behav 26:183–186
Deshmukh R, Sharma V, Mehan S, Sharma N, Bedi KL (2009) Amelioration of intracerebroventricular strepozotion induced cognitive dysfunction and oxidate stress by vinpocetine – a PDE1 inhibitor. Eur J Pharmacol 620:49–56
Devan BD, Sierra-Mercado D Jr, Jimenez M, Bowker JL, Duffy KB, Spangler EL, Ingram DK (2004) Phosphodiesterase inhibition by sildenafil citrate attenuates the learning impairment induced by blockade of cholinergic muscarinic receptors in rats. Pharmacol Biochem Behav 79:691–699
Dhir A, Kulkarni SK (2007a) Effect of addition of yohimbine (alpha-2-receptor antagonist) to the antidepressant activity of fluoxetine or venlafaxine in the mouse forced swim test. Pharmacology 80:239–243
Dhir A, Kulkarni SK (2007b) Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor. Eur J Pharmacol 568:177–185
Dlaboga D, Hajjhussein H, O’Donnell JM (2006) Regulation of phosphodiesterase-4 (PDE4) expression in mouse brain by repeat antidepressant treatment: comparison with rolipram. Brain Res 1096:104–112
Domek-Łopacińska KU, Strosznajder JB (2008) The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging. Brain Res 1216:68–77
Domek-Łopacińska KU, Strosznajder JB (2010) Cyclic GMP and nitric oxide synthase in aging and Alzheimer's disease. Mol Neurobiol 41:129–137
Doyle C, Hölscher C, Rowan MJ, Anwyl R (1996) The selective neuronal NO synthase inhibitor 7-nitroindazole blocks both long-term potentiation and depotentiation of field EPSPs in rat hippocampal CA1 in vivo. J Neurosci 16:418–424
Duman RS (2002) Pathophysiology of depression: the concept of synaptic plasticity. Eur Psychiatry 17:306–310
Duman RS, Malberg J, Thome J (1999) Neural plasticity to stress and antidepressant treatment. Biol Psychiatry 46:1181–1191
Dumaz N, Marais R (2003) Protein kinase A blocks Raf-1 activity by stimulating 14-3-3 binding and blocking Raf-1 interaction with Ras. J Biol Chem 278:29819–29823
Dunkern TR, Hatzelmann A (2007) Characterization of inhibitors of phosphodiesterase 1C on a human cellular system. FEBS J 274:4812–4824
Egan M, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M (2003) The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112:257–269
Einat H, Yuan P, Manji HK (2005) Increased anxiety-like behaviors and mitochondrial dysfunction in mice with targeted mutation of the Bcl-2 gene: further support for the involvement of mitochondrial function in anxiety disorders. Behav Brain Res 165:172–180
Engels P, Abdel’Al S, Hulley P, Lübbert H (1995) Brain distribution of four rat homologues of the Drosophila dunce cAMP phosphodiesterase. J Neurosci Res 41:169–178
Epp JR, Spritzer MD, Galea LA (2007) Hippocampus-dependent learning promotes survival of new neurons in the dentate gyrus at a specific time during cell maturation. Neuroscience 149:273–285
Esposito K, Reierson GW, Luo HR, Wu GS, Licinio J, Wong ML (2009) Phosphodiesterase genes and antidepressant treatment response: a review. Ann Med 41:177–185
Fatemi SH, King DP, Reutiman TJ, Folsom TD, Laurence JA, Lee S, Fan YT, Paciga SA, Conti M, Menniti FS (2008) PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia. Schizophr Res 101:36–49
Fawcett L, Baxendale R, Stacey P, McGrouther C, Harrow I, Soderling S, Hetman J, Beavo JA, Phillips SC (2000) Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci USA 97:3702–3707
Filgueiras CC, Krahe TE, Medina AE (2010) Phosphodiesterase type 1 inhibition improves learning in rats exposed to alcohol during the third trimester equivalent of human gestation. Neurosci Lett 473:202–207
Fink HA, Mac Donald R, Rutks IR, Nelson DB, Wilt TJ (2002) Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 162:1349–1360
Francis SH (2005) Phosphodiesterase 11 (PDE11): is it a player in human testicular function? Int J Impot Res 17:467–468
Francis SH, Lincoln TM, Corbin JD (1980) Characterization of a novel cGMP binding protein from rat lung. J Biol Chem 255:620–626
Francis SH, Busch JL, Corbin JD (2010) cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev 62:525–563
Frey U, Huang Y, Kandel ER (1993) Effects of cAMP simulate a late stage of LTP in hippocampal CA1 neurons. Science 260:1661–1664
Fujioka T, Fujioka A, Duman RS (2004) Activation of cAMP signaling facilitates themorphological maturation of newborn neurons in adult hippocampus. J Neurosci 24:319–328
Fujishige K, Kotera J, Omori K (1999) Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE 10A. Eur J Biochem 266:1118–1127
Gao Y, Deng K, Hou J, Bryson JB, Barco A, Nikulina E, Spencer T, Mellado W, Kandel ER, Filbin MT (2004) Activated CREB is sufficient to overcome inhibitors in myelin and promote spinal axon regeneration in vivo. Neuron 44:609–621
Garthwaite J, Boulton CL (1995) Nitric oxide signaling in the central nervous system. Annu Rev Physiol 57:683–706
Gong B, Vitolo OV, Trinchese F, Liu S, Shelanski M, Arancio O (2004) Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J Clin Invest 114:1624–1634
Gross-Langenhoff M, Hofbauer K, Weber J, Schultz A, Schultz JE (2006) camp is a ligand for the tandem GAF domain of human phosphodiesterase 10 and cGMP for the tandem GAF domain of phosphodiesterase 11. J Biol Chem 281:2841–2846
Guo J, Watson A, Kempson J, Carlsen M, Barbosa J, Stebbins K, Lee D, Dodd J, Nadler SG, McKinnon M, Barrish J, Pitts WJ (2009) Identification of potent pyrimidine inhibitors of phosphodiesterase 7 (PDE7) and their ability to inhibit T cell proliferation. Bioorg Med Chem Lett 19:1935–1938
Hajjhussein H, Suvarna NU, Gremillion C, Chandler LJ, O’Donnell JM (2007) Changes in NMDA receptor-induced cyclic nucleotide synthesis regulated the age-dependent increase in PDE4A expression in primary cortical cultures. Brain Res 1149:58–68
Haley JE, Malen PL, Chapman PF (1993) Nitric oxide synthase inhibitors block long term potentiation induced by weak but not strong tetanic stimulation at physiological brain temperatures in rat hippocampal slices. Neurosci Lett 160:85–88
Han P, Zhu XY, Michaeli T (1997) Alternative splicing of the high affinity cAMP-specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart. J Biol Chem 272:16152–16157
Han P, Werber J, Surana M, Fleischer N, Michaeli T (1999) The calcium/calmodulin-dependent phosphodiesterase PDE1C down-regulates glucose-induced insulin secretion. J Biol Chem 274:22337–22344
Hartell NA (1996) Inhibition of cGMP breakdown promotes the induction of cerebellar long-term depression. J Neurosci 16:2881–2890
Hebb ALO, Robertson HA, Denovan-Wright EM (2004) Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington’s Disease transgenic mice prior to the onset of motor symptoms. Neuroscience 123:967–981
Hebb AL, Robertson HA, Denovan-Wright EM (2008) Phosphodiesterase 10A inhibition is associated with locomotor and cognitive deficits and increased anxiety in mice. Eur Neuropsychopharmacol 18:339–363
Heikaus CC, Pandit J, Klevit RE (2009) Cyclic nucleotide binding GAF domains from phosphodiesterases: structural and mechanistic insights. Structure 17:1551–1557
Holtmaat AJ, Trachtenberg JT, Wilbrecht L, Shepherd GM, Zhang X, Knott GW, Svoboda K (2005) Transient and persistent dendritic spines in the neocortex in vivo. Neuron 45:279–291
Houslay MD (2001) PDE4 cAMP-specific phosphodiesterases. Prog Nucleic Acid Res Mol Biol 69:249–315
Houslay MD (2010) Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends Biochem Sci 35:91–100
Houslay MD, Schafer P, Zhang KY (2005) Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 10:1503–1519
Houslay MD, Baillie GS, Maurice DH (2007) cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling. Circ Res 100:950–966
Hu H, McCaw EA, Hebb AL, Gomez GT, Denovan-Wright EM (2004) Mutant huntingtin affects the rate of transcription of striatum-specific isoforms of phosphodiesterase 10A. Eur J Neurosci 20:3351–3363
Impey S, Mark M, Villacres EC, Poser S, Chavkin C, Storm DR (1996) Induction of CRE-mediated gene expression by stimuli that generate long-lasting LTP in area CA1 of the hippocampus. Neuron 16:973–982
Itoh T, Tokumura M, Abe K (2004) Effects of rolipram, a phosphodiesterase 4 inhibitor, in combination with imipramine on depressive behavior, CRE-binding activity and BDNF level in learned helplessness rats. Eur J Pharmacol 498:135–142
Juilfs DM, Fulle HJ, Zhao AZ, Houslay MD, Garbers DL, Beavo JA (1997) A subset of olfactory neurons that selectively express cGMP-stimulated phosphodiesterase (PDE2) and guanylyl cyclase-D define a unique olfactory signal transduction pathway. Proc Natl Acad Sci USA 94:3388–3395
Kadoshima-Yamaoka K, Murakawa M, Goto M, Tanaka Y, Inoue H, Murafuji H, Nagahira A, Hayashi Y, Nagahira K, Miura K, Nakatsuka T, Chamoto K, Fukuda Y, Nishimura T (2009) ASB16165, a novel inhibitor for phosphodiesterase 7A (PDE7A), suppresses IL-12-induced IFN-gamma production by mouse activated T lymphocytes. Immunol Lett 122:193–197
Kaulen P, Brüning G, Schneider HH, Sarter M, Baumgarten HG (1989) Autoradiographic mapping of a selective cyclic adenosine monophosphate phosphodiesterase in rat brain with the antidepressant [3H]rolipram. Brain Res 503:229–245
Kelly MP, Brandon NJ (2009) Differential function of phosphodiesterase families in the brain: gaining insights through the use of genetically modified animals. Prog Brain Res 179:67–73
Kelly MP, Logue SF, Brennan J, Day JP, Lakkaraju S, Jiang L, Zhong X, Tam M, Sukoff Rizzo SJ, Platt BJ, Dwyer JM, Neal S, Pulito VL, Agostino MJ, Grauer SM, Navarra RL, Kelley C, Comery TA, Murrills RJ, Houslay MD, Brandon NJ (2010) Phosphodiesterase 11A in brain is enchriched in ventral hippocampus and deletion cause psychiatric disease related phenotypes. Neuroscience 107:8457–8462
Kleppisch T (2009) Phosphodiesterases in the central nervous system. Handb Exp Pharmacol 191:71–92
Kobayashi T, Gamanuma M, Sasaki T, Yamashita Y, Yuasa K, Kotera J, Omori K (2003) Molecular comparison of rat cyclic nucleotide phosphodiesterase 8 family: unique expression of PDE8B in rat brain. Gene 319:21–31
Kotaleski JH, Blackwel Kim T (2010) Modelling the molecular mechanisms of synaptic plasticity using systems biology approaches. Neuroscience 11:239–249
Kruuse C, SergeiD R, Tejvir S (2001) The role of cGMP hydrolyzing phosphodiesterase 1 and 5 in cerebral artery dilatation. Eur J Pharmacol 420:55–65
Lee R, Wolda S, Moon E, Esselstyn J, Hertel C, Lerner A (2002) PDE7A is expressed in human B-lymphocytes and is up-regulated by elevation of intracellular cAMP. Cell Signal 14:277–284
Lehericy S, Gerardin E (2002) Normal functional imaging of the basal ganglia. Epileptic Disord 4:S23–S30
Lepage M, Ghaffar O, Nyberg L, Tulving E (2000) Prefrontal cortex and episodic memory retrieval mode. Proc Natl Acad Sci USA 97:506–511
Li L, Yee C, Beavo JA (1999) CD3- and CD28-Dependent Induction of PDE7 Required for T Cell Activation. Science 283:848–851
Li YF, Huang Y, Amsdell SL, Xiao L, O’Donnell JM, Zhang HT (2009) Antidepressant- and anxiolytic-like effects of the phosphodiesterase-4 (PDE4) inhibitor rolipram on behavior depend on cyclic AMP-response element binding protein (CREB)-mediated neurogenesis in the hippocampus. Neuropsychopharmacology 34:2404–2419
Liebenberg N, Harvey BH, Brand L, Brink CB (2010) Antidepressant-like properties of phosphodiesterase type 5 inhibitors and cholinergic dependency in a genetic rat model of depression. Behav Pharmacol 21(5–6):540–547
Lin CS (2004) Tissue expression, distribution, and regulation of PDE5. Int J Impot Res 16:8–10
Lonze BE, Ginty DD (2002) Function and regulation of CREB family transcription factors in the nervous system. Neuron 35:605–623
Loughney K, Snyder PB, Uher L, Rosman GJ, Ferguson K, Florio VA (1999) Isolation and characterization of PDE10A, a novel human 3′, 5′-cyclic nucleotide phosphodiesterase. Gene 234:109–117
Loughney K, Taylor J, Florio VA (2005) Original research 3′, 5′-Cyclic nucleotide phosphodiesterase 11A: localization in human tissues. Int J Impot Res 17:320–325
Lu YF, Kandel ER, Hawkins RD (1999) Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus. J Neurosci 19:10250–10261
Lucassen H (2004) Pediatric hospice: a second home. Pflege Z 57:854–855
Lugnier C (2006) Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109:366–398
MacKenzie SJ, Baillie GS, McPhee I, Bolger GB, Houslay MD (2000) ERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases. The involvement of COOH-terminal docking sites and NH2-terminal UCR regions. J Biol Chem 275:16609–16617
MacKenzie SJ, Baillie GS, McPhee I, MacKenzie C, Seamons R, McSorley T, Millen J, Beard MB, van Heeke G, Houslay MD (2002) Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in upstream conserved region 1 (UCR1). Br J Pharmacol 136:421–433
Makhlouf A, Kshirsagar A, Niederberger C (2006) Phosphodiesterase 11: a brief review of structure, expression and function. Int J Impot Res 18:501–509
Martinez SE, Beavo JA, Hol WG (2002) GAF domains: two-billion-year-old molecular switches that bind cyclic nucleotides. Mol Interv 2:317–323
Masood A, Nadeem A, Mustafa SJ, O’Donnell JM (2008) Reversal of oxidative stress-induced anxiety by inhibition of phosphodiesterase-2 in mice. J Pharmacol Exp Ther 326:369–379
Masood A, Huang Y, Hajjhussein H, Xiao L, Li H, Wang W, Hamza A, Zhan CG, O’Donnell JM (2009) Anxiolytic effects of phosphodiesterase-2 inhibitors associated with increased cGMP signaling. J Pharmacol Exp Ther 331:690–699
Matousovic K, Grande JP, Chini CC, Chini EN, Dousa TP (1995) Inhibitors of cyclic nucleotide phosphodiesterase isozymes type-III and type-IV suppress mitogenesis of rat mesangial cells. J Clin Invest 96:401–410
Maurice DH, Haslam RJ (1990) Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol 37:671–681
McPhee I, Cochran S, Houslay MD (2001) The novel long PDE4A10 cyclic AMP phosphodiesterase shows a pattern of expression within brain that is distinct from the long PDE4A5 and short PDE4A1 isoforms. Cell Signal 13:911–918
Mendelovic S, Doron A, Eilat E (1997) Short note: can depressive patients exploit the immune system for suicide. Med Hypotheses 49:445–446
Mendelovic S, Doron A, Shoenfeld Y (1999) Depression and the immune system. Harefuah 136:88–91
Menniti FS, Faraci WS, Schmidt CJ (2006) Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov 5:660–670
Menniti FS, Chappie TA, Humphrey JM, Schmidt CJ (2007) Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia. Curr Opin Investig Drugs 8:54–59
Meyer MR, Angele A, Kremmer E, Kaupp B, Muller F (2000) A cGMP-signaling pathway in subset of olfactory sensory neurons. PNAS 97:10595–10600
Millar JK, Pickard BS, Mackie S, James R, Christie S, Buchanan SR (2005) DISCI and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science 310:1187–1191
Millar JK, Mackie S, Clapcote SJ, Murdoch H, Pickard BS, Christie S, Muir WJ, Blackwood DH, Roder JC, Houslay MD, Porteous DJ (2007) Disrupted in schizophrenia 1 and phosphodiesterase 4B: towards an understanding of psychiatric illness. J Physiol 584:401–405
Miller CL, Oikawa M, Cai Y, Wojtovich AP, Nagel DJ, Xu X, Xu H, Florio V, Rybalkin SD, Beavo JA, Chen YF, Li JD, Blaxall BC, Abe J, Yan C (2009) Role of Ca2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy. Circ Res 105:956–964
Miro X, Perez-Torres S, Palacios JM, Puigdomenech P, Mengod G (2001) Differential distribution of cAMP-specific phosphodiesterase 7A mRNA in rat brain and peripheral organs. Synapse 40:201–204
Miró X, Pérez-Torres S, Puigdomènech P, Palacios JM, Mengod G (2002) Differential distribution of PDE4D splice variant mRNAs in rat brain suggests association with specific pathways and presynaptical localization. Synapse 45:259–269
Miyamoto E (2006) Molecular mechanism of neuronal plasticity: induction and maintenance of long-term potentiation in the hippocampus. J Pharmacol Sci 100:433–442
Molnar P, Gaal L (1992) Effect of different subtypes of cognition enhancers on longterm potentiation in the rat dentate gyrus in vitro. Eur J Pharmacol 215:17–22
Monfort P, Muñoz MD, Kosenko E, Llansola M, SÃnchez-Pérez A, Cauli O, Felipo V (2004) Sequential activation of soluble guanylate cyclase, protein kinase G and cGMP-degrading phosphodiesterase is necessary for proper induction of long-term potentiation in CA1 of hippocampus. Alterations in hyperammonemia. Neurochem Int. 2004 Nov;45(6):895–901
Monti B, Berteotti C, Contestabile A (2006) Subchronic Rolipram Delivery Activates Hippocampal CREB and Arc, Enhances Retention and Slows Down Extinction of Conditioned Fear. Neuropsychopharmacology 31:278–286
Mori F, Pérez-Torres S, De Caro R, Porzionato A, Macchi V, Beleta J, Gavaldà A, Palacios JM, Mengod G (2010) The human area postrema and other nuclei related to the emetic reflex express cAMP phosphodiesterases 4B and 4D. J Chem Neuroanat 40:36–42
Mueller EM, Hofmann SG, Cherry JA (2010) The type IV phosphodiesterase inhibitor rolipram disturbs expression and extinction of conditioned fear in mice. Neuropharmacology 59:1–8
Murata T, Shimizu K, Hiramoto K, Tagawa T, Murata T, Shimizu K, Hiramoto K, Tagawa T (2009) Phosphodiesterase 3 (PDE3): structure, localization and function. Cardiovasc Hematol Agents Med Chem 7:206–211
Murdoch H, Mackie S, Collins DM, Hill EV, Bolger GB, Klussmann E, Porteous DJ, Millar JK, Houslay MD (2007) Isoform-selective susceptibility DISC1/phosphodiesterase-4 complexes to dissociation by elevated intracellular cAMP levels. J Neurosci 27:9513–9524
Nagel DJ, Aizawa T, Jeon KI, Liu W, Mohan A, Wei H (2006) Role of nuclear Ca2+/calmodulin-stimulated phos- phodiesterase 1A in vascular smooth muscle cell growth and survival. Circ Res 98:777–784
Navakkode S, Sajikumar S, Frey JU (2005) Mitogen-activated protein kinase-mediated reinforcement of hippocampal early long-term depression by the type IV-specific phosphodiesterase inhibitor rolipram and its effect on synaptic tagging. J Neurosci 25:10664–10670
Nguyen RV, Woo NH (2003) Regulation of hippocampal synaptic plasticity by cyclic AMP-dependent protein kinases. Prog Neurobiol 71:401–437
Nikolaev VO, Gambaryan S, Engehardt S, Walter U, Lohse MJ (2005) Real-time monitoring of the PDE2 a activity of live cells: hormone-stimulate camp hydrolysis is faster than hormone-stimulated cAMP synthesis. J Biol Chem 280:1716–1719
Numata S, Ueno S, Iga J, Song H, Nakataki M, Tayoshi S, Sumitani S, Tomotake M, Itakura M, Sano A, Ohmori TJ (2008) Positive association of the PDE4B (phosphodiesterase 4B) gene with schizophrenia in the Japanese population. Psychiatr Res 43:7–12
O’Donnell JM, Zhang HT (2004) Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol Sci 25:158–163
Obara Y, Nakahata N, Stork PJ (2009) cAMP signaling for ERK activation in neuronal cells. Nippon Yakurigaku Zasshi 133:63–68
O’Conner MS, Steiner JM, Roussel AJ, Williams DA, Meddings JB, Pipers F, Cohen ND (2004) Evaluation of urine sucrose concentration for detection of gastric ulcers in horses. Am J Vet Res 65:31–39
Oike Y, Hata A, Mamiya T, Kaname T, Noda Y, Suzuki M, Yasue H, Nabeshima T, Araki K, Yamamura K (1999) Truncated CBP protein leads to classical Rubinstein-Taybi syndrome phenotypes in mice: implications for a dominant-negative mechanism. Hum Mol Genet 8:387–396
Oliveira RF, Terrin A, Di Benedetto G, Cannon RC, Koh W, Kim M, Zaccolo M, Blackwell KT (2010) The role of type 4 Phosphodiesterases in generating microdomains of cAMP: large scale stochastic simulations. PLoS ONE 5:e11725
Olton DS (1983) Memory functions and the hippocampus. In: Seifert W (ed) Neurobiology of the hippcampus. Academic, London, pp 335–369
Oray S, Majewska A, Sur M (2004) Dendritic spine dynamics are regulated by monocular deprivation and extracellular matrix degradation. Neuron 44:1021–1030
Paizanis E, Hamon M, Lanfumey L (2007) Hippocampal neurogenesis, depressive disorders, and antidepressant therapy. Neural Plast. 2007:737–754
Palmer D, Jimmo SL, Raymond DR, Wilson LS, Carter RL, Maurice DH (2007) Protein kinase A phosphorylation of human phosphodiesterase 3B promotes 14-3-3 protein binding and inhibits phosphatase-catalyzed inactivation. J Biol Chem 282:9411–9419
Pause BM, Miranda A, Goder R, Aldenhoff JB, Ferstl R (2001) Reduced olfactory performance in patients with major depression. J Psychiatr Res 35:271–277
Pérez-Torres S, Miró X, Palacios JM, Puigdoménech P, Mengod G (2001) PDE4 isozymes expression in human brain examined by in situ hybridization histochemistry and rolipram binding sites. Comparison with monkey and rat brains. J Chem Neuroanat 20:349–374
Pelligrino DA, Wang Q (1998) Cyclic nucleotide crosstalk and the regulation of cerebral vasodilation. Prog Neurobiol 56:1–18
Pereira A Jr, Furlan FA (2010) Astrocytes and human cognition:Modeling information integration and modulation of neuronal activity. Neurobiology 1046:1–16
Pérez-Torres S, Miró X, Palacios JM, Cortés R, Puigdoménech P, Mengod G (2000) Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and[3H]rolipram binding autoradiography. Comparison with monkey and rat brain. J Chem Neuroanat 20:349–374
Pérez-Torres S, Cortés R, Tolnay M, Probst A, Palacios JM, Mengod G (2003) Alteration of phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer’s disease brains examined by in situ hybridization. Exp Neurol 182:322–334
Pickard BS, Thomson PA, Christoforou A, Evans KL, Morris SW, Porteous DJ, Blackwood DH, Muir WJ (2007) The PDE4B gene confers sex-specific protection against schizophrenia. Psychiatr Genet 17:129–133
Pilz RB, Broderick KE (2005) Role of cyclic GMP in gene regulation. Front Biosci 10:1239–1268
Pollatos O, Kopietz R, Linn J, Albrecht J, Sakar V, Anzinger A, Schandry R, Wiesmann M (2007) Emotional stimulation alters olfactory sensitivity and odor judgment. Chem Senses 32:583–589
Prickaerts J, van Staveren WC, Sik A, Markerink-van Ittersum M, Niewöhner U, van der Staay FJ, Blokland A, de Vente J (2002) Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat. Neuroscience 113:351–361
Prickaerts J, Sik A, van Staveren WC, Koopmans G, Steinbusch HW, van der Staay FJ, de Vente J, Blokland A (2004) Phosphodiesterase type 5 inhibition improves early memory consolidation of object information. Neurochem Int 45:915–928
Puzzo D, Vitolo O, Trinchese F, Jacob JP, Palmeri A, Arancio O (2005) Amyloid-beta peptide inhibits activation of the nitric oxide/cGMP/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity. J Neurosci 25:6887–6897
Puzzo D, Staniszewski A, Deng SX, Privitera L, Leznik E, Liu S, Zhang H, Feng Y, Palmeri A, Landry DW, Arancio O (2009) Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-load in an Alzheimer’s disease mouse model. J Neurosci 29:8075–8086
Pyne NJ, Cooper ME, Houslay MD (1986) Identification and characterization of both the cytosolic and particulate forms of cyclic GMP-stimulated cyclic AMP phosphodiesterase from rat liver. Biochem J 234:325–334
Quiroz JA, Machado-Vieira R, Zarate CA Jr, Manji HK (2010) Novel insights into lithium’s mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology 62:50–60
Ramos BP, Birnbaum SG, Lindenmayer I, Newton SS, Duman RS, Arnsten AFT (2003) Dysregulation of protein kinase A signaling in the aged prefrontal cortex: new strategy for treating age-related cognitive decline. Neuron 40:835–845
Ramos BP, Stark D, Verduzco L, van Dyck CH, Arnsten AF (2006) Alpha2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animals. Learn Mem 13:770–776
Rapoport M, van Reekum R, Mayberg H (2000) The role of the cerebellum in cognition and behavior: a selective review. J Neuropsychiatry Clin Neurosci 12:193–198
Reinés A, Cereseto M, Ferrero A, Sifonios L, Podestá MF, Wikinski S (2008) Maintenance treatment with fluoxetine is necessary to sustain normal levels of synaptic markers in an experimental model of depression: correlation with behavioral response. Neuropsychopharmacology 33:1896–1908
Reneerkens OA, Rutten K, Steinbusch HW, Blokland A, Prickaerts J (2009) Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology 202:419–443
Reyes-Irisarri E, Pérez-Torres S, Mengod G (2005) Neuronal expression of cAMP-specific phosphodiesterase 7B mRNA in the rat brain. Neuroscience 132:1173–1185
Rose GM, Hopper A, De Vivo M, Tehim A (2005) Phosphodiesterase inhibitors for cognitive enhancement. Curr Pharm Des 11:3329–3334
Rutten K, Prickaerts J, Blokland A (2006) Rolipram reverses scopolamine-induced and time-dependent memory deficits in object recognition by diVerent mechanisms of action. Neurobiol Learn Mem 85:132–138
Rutten K, Prickaerts J, Hendrix M, van der Staay FJ, Sik A, Blokland A (2007) Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors. Eur J Pharmacol 558:107–112
Rutten K, Misner DL, Works M, Blokland A, Novak TJ, Santarelli L, Wallace TL (2008) Enhanced long-term potentiation and impaired learning in phosphodiesterase 4D-knockout (PDE4D) mice. Eur J Neurosci 28:625–632
Rybalkin SD, Rybalkina I, Beavo JA, Bornfeldt KE (2002) Cyclic nucleotide phosphodiesterase 1C promotes human J. of Cardiovasc. Trans. Res. J. of Cardiovasc. Trans. Res. arterial smooth muscle cell proliferation. Circ Res 90:151–157
Sasaki T, Yuasa K, Omori K (2000) Identification of human PDE7B, a cAMP specific phosphodiesterase. Biochem Biophys Res Comm 271:575–583
Sasaki T, Kotera J, Omori K (2002) Novel alternative splice variants of rat phosphodiesterase 7B showing unique tissue-specific expression and phosphorylation. Biochem J 361:211–220
Sasaki T, Kotera J, Omori K (2004) Transcriptional activation of phosphodiesterase 7B1 by dopamine D1 receptor stimulation through the cyclic AMP/cyclic AMP-dependent protein kinase/cyclic AMP-response element binding protein pathway in primary striatal neurons. J Neurochem 89:474–483
Schaak S, Cayla C, Lymperopoulos A, Flordellis C, Cussac D, Denis C, Paris H (2000) Transcriptional down-regulation of the human alpha2C-adrenergic receptor by cAMP. Mol Pharmacol 58:821–827
Schmidt CJ (2010) Phosphodiesterase inhibitors as potential cognition enhancing agents. Curr Top Med Chem 10:222–230
Seeger TF, Bartlett B, Coskran TM, Culp JS, James LC, Krull DL, Lanfear J, Ryan AM, Schmidt CJ, Strick CA, Varghese AH, Williams RD, Wylie PG, Menniti FS (2003) Immunohistochemical localization of PDE10A in the rat brain. Brain Res 985:113–126
Sette C, Iona S, Conti M (1994) The short-term activation of a rolipramsensitive, cAMP-specific phosphodiesterase by thyroid-stimulating hormone in thyroid FRTL-5 cells is mediated by a cAMP-dependent phosphorylation. J Biol Chem 269:9245–9252
Singh N, Parle M (2003) Sildenafil improves acquisition and retention of memory in mice. Indian J Physiol Pharmacol 47:318–324
Siuciak JA (2008) The role of phosphodiesterases in schizophrenia: therapeutic implications. CNS Drugs 22:983–993
Siuciak JA, McCarthy SA, Chapin DS, Fujiwara RA, James LC, Williams RD, Stock JL, McNeish JD, Strick CA, Menniti FS, Schmidt CJ (2006) Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology 51:374–385
Siuciak JA, Chapin DS, McCarthy SA, Martin AN (2007) Antipsychoticprofole of rolipram: efficacy in rat and reduced sensitivity in mice deficient in the phosphodiesterase-4B(PDE4B) enzyme. Psychopharmacology (Berl) 192:415–424
Siuciak JA, McCarthy SA, Chapin DS, Martin AN (2008) Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. Psychopharmacology 197:115–126
Sklar P, Gabriel SB, McInnis MG, Bennett P, Lim YM, Tsan G, Schaffner S, Kirov G, Jones I, Owen M, Craddock N, DePaulo JR, Lander ES (2002) Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Mol Psychiatry 7:579–593
Smith SJ, Cieslinski LB, Newton R, Donnelly LE, Fenwick PS, Nicholson AG, Barnes PJ, Barnette MS, Giembycz MA (2004) Discovery of BRL 50481 [3-(N, N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. Mol Pharmacol 66:1679–1689
Soderling SH, Bayuga SJ, Beavo JA (1999) Isolation and characterization of a dual-substrated phosphodiesterase gene family: PDE10A. Proc Natl Acad Sci USA 96:7071–7076
Souness JE, Aldous D, Sargent C (2000) Immunosuppressive and antiinfl ammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 47:127–162
Ster J, de Bock F, Bertaso F, Abitbol K, Daniel H, Bockaert J, Fagni L (2009) Epac mediates PACAP-dependent long-term depression in the hippocampus. J Physiol 587:101–113
Strick CA, James LC, Fox CB, Seeger TF, Menniti FS, Schmidt CJ (2010) Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A. Neuropharmacology 58:444–451
Surapisitchat J, Jeon KI, Yan C, Beavo JA (2007) Differential regulation of endothelial cell permeability by cGMP via phosphodiesterases 2 and 3. Circ Res 101:811–818
Suvarna NU, O’Donnell JM (2002) Hydrolysis of N-methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus. J Pharmacol Exp Ther 302:249–256
Takahashi M, Terwilliger R, Lane C, Mezes PS, Conti M, Duman RS (1999) Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms. J Neurosci 19:610–618
Tanis KQ, Duman RS (2007) Intracellular signaling pathways pave roads to recovery for mood disorders. Ann Med 39:531–544
Taylor JR, Birnbaum SG, Ubriani R, Arnsten AFT (1999) Activation of protein kinase A in prefrontal cortex impairs working memory performance. J Neurosci 19:RC23
Taylor RE, Shows KH, Zhao Y, Pittler SJ (2001) A PDE6A promoter fragment directs transcription predominantly in the photoreceptor. Biochem Biophys Res Commun 282:543–547
Teng FY, Tang BL (2006) Axonal regeneration in adult CNS neurons-signaling molecules and pathways. J Neurochem 96:1501–1508
Thompson PE, Manganiello V, Degerman E (2007) Re-discovering PDE3 inhibitors – new opportunities for a long neglected target. Curr Top Med Chem 7:421–436
Titus SA, Li X, Southall N, Lu J, Inglese J, Brasch M, Austin CP, Zheng W (2008) A cell-based PDE4 assay in 1536-well plate format for high-throughput screening. J Biomol Screen 13:609–618
Torras-Llort M, Azorin F (2003) Functional characterization of the human phosphodiesterase 7A1 promoter. Biochem J 373:835–843
Uthayathas S, Karuppagounder SS, Thrash BM, Parameshwaran K, Suppiramaniam V, Dhanasekaran M (2007) Versatile effects of sildenafil: recent pharmacological applications. Pharmacol Rep 59:150–163
Valera E, Sánchez-Martín FJ, Ferrer-Montiel AV, Messeguer A, Merino JM (2008) NMDA-induced neuroprotection in hippocampal neurons is mediated through the protein kinase A and CREB (cAMP-response element-binding protein) pathway. Neurochem Int 58:148–154
Van der Staay FJ, Rutten K, Bärfacker L, Devry J, Erb C, Heckroth H, Karthaus D, Tersteegen A, van Kampen M, Blokland A, Prickaerts J, Reymann KG, Schröder UH, Hendrix M (2008) The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents. Neuropharmacology 55:908–918
van Donkelaar EL, Rutten K, Blokland A, Akkerman S, Steinbusch HW, Prickaerts J (2008) Phosphodiesterase 2 and 5 inhibition attenuates the object memory deficit induced by acute tryptophan depletion. Eur J Pharmacol 600:98–104
Van Staveren WCG, Markerink-Van Ittersum M, Steinbusch HWM, De Vente J (2001) The effect of phosphodiesterase inhibition on cyclic GMP and cyclic AMP accumulation in the hippocampus of the rat. Brain Res 888:275–286
Van Staveren WC, Steinbusch HW, Markerink-van Ittersum M, Repaske DR, Goy MF, Kotera J, Omori K, Beavo JA, De Vente J (2003) mRNA expression patterns of the cGMP-hydrolyzing phosphodiester- ases types 2, 5, and 9 during development of the rat brain. J Comp Neurol 467:566–580
Vecsey CG, Baillie GS, Jaganath D, Havekes R, Daniels A, Wimmer M, Huang T, Brown KM, Li XY, Descalzi G, Kim SS, Chen T, Shang YZ, Zhuo M, Houslay MD, Abel T (2009) Sleep deprivation impairs cAMP signalling in the hippocampus. Nature 461:1122–1125
Viana RJ, Fonseca MB, Ramalho RM, Nunes AF, Rodrigues CM (2010) Organelle stress sensors and cell death mechanisms in neurodegenerative diseases. CNS Neurol Disord Drug Targets 9(6):679–692
Wachtel H (1982) Characteristic behavioural alterations in rats induced by rolipram and other selective adenosine cyclic 3', 5'-monophosphate phosphodiesterase inhibitors. Psychopharmacol (Berl) 77:309–316
Weeks JL, Zoraghi R, Francis SH, Corbin JD (2007) N-Terminal domain of phosphodiesterase-11A4 (PDE11A4) decreases affinity of the catalytic site for substrates and tadalafil, and is involved in oligomerization. Biochemistry 46:10353–10364
Whitaker CM, Wei H (2009) An alternate cAMP pathway Epac promotes hippocampal long-term depression. J Physiol 587:3067–3068
Wong ML, Whelan F, Deloukas P, Whittaker P, Delgado M, Cantor RM, McCann SM, Licinio J (2006) Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response. Proc Natl Acad Sci USA 103:15124–15129
Woolfrey KM, Srivastava DP, Photowala H, Yamashita M, Barbolina MV, Cahill ME, Xie Z, Jones KA, Quilliam LA, Prakriya M, Penzes P (2009) Epac2 induces synapse remodeling and depression and its disease-associated forms alter spines. Nat Neurosci 12:1275–1284
Wu AY, Tang XB, Martinez SE, Ikeda K, Beavo JA (2004) Molecular determinants for cyclic nucleotide binding to the regulatory domains of phosphodiesterase 2A. J Biol Chem 279:37928–37938
Wunder F, Tersteegen A, Rebmann A, Erb C, Fahrig T, Hendrix M (2005) Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line. Mol Pharmacol 68:1775–1781
Xie Z, Adamowicz WO, Eldred WD, Jakowski AB, Kleiman RJ, Morton DG, Stephenson DT, Strick CA, Williams RD, Menniti F (2006) Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase. Neuroscience 139:597–607
Yang G, McIntyre KW, Townsend RM, Shen HH, Pitts WJ, Dodd JH, Nadler SG, McKinnon M, Watson AJ (2003) Phosphodiesterase 7A-deficient mice have functional T cells. J Immunol 171:6414–6420
Yuasa K, Kanoh Y, Okumura K, Omori K (2001) Genomic organization of the human phosphodiesterase PDE11A gene, Evolutionary relatedness with other PDEs containing GAF domains. Eur J Biochem 268:168–178
Zaccolo M, Movsesian MA (2007) cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ Res 100:1569–1578
Zhan Y, Zhang HT, O’Donnel JM (2003) Antidepressant-induced increase in high-affinity rolipram binding sites in rat brain: dependence on noradrenergic and serotonergic function. J Pharmacol Exp Ther 307:246–253
Zhang HT (2009) Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs. Curr Pharm Des 15:1687–1698
Zhang HT, O’Donnell JM (2000) Effects of rolipram on scopolamine-induced impairment of working and reference memory in the radial-arm maze tests in rats. Psychopharmacology 150:311–316
Zhang HT, Crissman AM, Dorairaj NR, Chandler LJ, O’Donnell JM (2000) Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism. Neuropsychopharmacology 23:198–204
Zhang HT, Huang Y, Jin SL, Frith SA, Suvarna N, Conti M, O'Donnell JM (2002a) Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology 27:587–595
Zhang R, Wang Y, Zhang L, Zhang Z, Tsang W, Lu M, Zhang L, Chopp M (2002b) Sildenafi l (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke 33:2675–2680
Zhang HT, Zhao Y, Huang Y, Dorairaj NR, Chandler LJ, O’Donnell JM (2004) Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus. Neuropsychopharmacology 29:1432–1439
Zhang HT, Huang Y, Suvarna NU, Deng C, Crissman AM, Hopper AT, De Vivo M, Rose GM, O'Donnell JM (2005) Effects of the novel PDE4 inhibitors MEM1018 and MEM1091 on memory in the radial-arm maze and inhibitory avoidance tests in rats. Psychopharmacology 179:613–619
Zhang L, Zhang Z, Zhang RL, Cui Y, LaPointe MC, Silver B, Chopp M (2006) Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke. Brain Res 1118:192–198
Zhang HT, Huang Y, Masood A, Stolinski LR, Li Y, Zhang L, Dlaboga D, Jin SL, Conti M, O’Donnell JM (2008) Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B (PDE4B). Neuropsychopharmacology 33:1611–1623
Zhao J, Harada N, Kurihara H, Nakagata N, Okajima K (2010) Cilostazol improves cognitive function in mice by increasing the production of insulin-like growth factor-I in the hippocampus. Neuropharmacology 58:774–783
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Xu, Y., Zhang, HT., O’Donnell, J.M. (2011). Phosphodiesterases in the Central Nervous System: Implications in Mood and Cognitive Disorders. In: Francis, S., Conti, M., Houslay, M. (eds) Phosphodiesterases as Drug Targets. Handbook of Experimental Pharmacology, vol 204. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-17969-3_19
Download citation
DOI: https://doi.org/10.1007/978-3-642-17969-3_19
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-17968-6
Online ISBN: 978-3-642-17969-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)